Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Inventory Average (2018 - 2025)

Ultragenyx Pharmaceutical has reported Inventory Average over the past 8 years, most recently at $52.1 million for Q4 2025.

  • Quarterly Inventory Average rose 17.96% to $52.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $52.1 million through Dec 2025, up 17.96% year-over-year, with the annual reading at $48.5 million for FY2025, 22.83% up from the prior year.
  • Inventory Average was $52.1 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $49.3 million in the prior quarter.
  • Over five years, Inventory Average peaked at $52.1 million in Q4 2025 and troughed at $12.8 million in Q1 2021.
  • The 5-year median for Inventory Average is $28.7 million (2023), against an average of $30.4 million.
  • Year-over-year, Inventory Average rose 11.3% in 2021 and then surged 56.82% in 2023.
  • A 5-year view of Inventory Average shows it stood at $15.7 million in 2021, then skyrocketed by 54.72% to $24.3 million in 2022, then skyrocketed by 35.29% to $32.9 million in 2023, then surged by 34.31% to $44.2 million in 2024, then increased by 17.96% to $52.1 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Inventory Average are $52.1 million (Q4 2025), $49.3 million (Q3 2025), and $46.3 million (Q2 2025).